Plaques were quantitated, and the mean plaque count per slice was recorded for each mouse. deficits in transgenic AD model mice. We also found that early software of VPA was important for alleviating memory TNFRSF1B space deficits of AD model mice. Our study suggests that VPA may be beneficial in the prevention and treatment of AD. Alzheimer’s disease (AD) is the most common neurodegenerative disorder leading to dementia. Neuritic plaques, neurofibrillary tangles, and neuronal loss represent the main histological hallmarks observed in AD brains. Amyloid -protein (A), the central component of senile plaques, is definitely produced from sequential endoproteolytic cleavages of the type 1 transmembrane glycoprotein -amyloid precursor protein (APP) by – and -secretase (1). -Site APP cleaving enzyme 1 (BACE1) is the -secretase in vivo (26). -Secretase is an atypical multimeric membrane-protein aspartic protease composed of at least four subunits: presenilin (PS1 or PS2), nicastrin (Nct), APH-1 (APH-1aL, APH-1aS, or APH-1b), and PEN-2 (711). More recently, two additional proteins, CD147 and TMP21, were found to be closely associated with the -secretase complex (12,13).The components of the -secretase complex are tightly regulated with each other, and PS1 is generally believed to be its catalytic core (14,15). Another important substrate of -secretase is definitely Notch, whose intracellular website (NICD) is definitely released upon -secretase cleavage and translocates to the nucleus, where it can activate transcription of downstream target genes (8,10). In addition to its part in Notch signaling and APP processing, -secretase is also involved in regulating intramembraneous proteolysis of many additional type I integral membrane proteins, such as Jagged, Delta, E-cadherin, ErbB-4, Nectin-1, CD44, and LRP (1622). Missense mutations in the PS1 and PS2 genes are major causes of early-onset familial AD (2325). Even though underlying mechanism of AD neurodegeneration is currently unclear, A accumulation appears to play a critical role in AD pathogenesis. Valproic acid (VPA) is definitely one of four first-line antiepileptic medicines being increasingly used in the treatment of bipolar disorder. Like additional anticonvulsants, VPA inhibits sodium, potassium, and calcium channel functions. Although its direct in vivo target has yet to be definitively recognized (26), VPA may enhance -aminobutyric acid transmission (27). VPA has been found to activate extracellular signal-regulated kinase, a protein kinase known to regulate AP-1 function, and mediate neurotrophic reactions (28). VPA treatment could lead to ML348 a change in glycogen synthase kinase (GSK-3) and histone deacetylase (HDAC) activity ML348 (29). Furthermore, VPA, like lithium, regulates the Wnt signaling pathway by increasing -catenin manifestation (30). Improved -catenin manifestation is also seen after treatment with the chemically unrelated HDAC inhibitor trichostatin A. This mechanism may clarify some effects of VPA on gene manifestation and neurodevelopment (31). It has been demonstrated that improved histone acetylation by HDAC inhibitors facilitates synaptogenesis and enhances learning and memory space, suggesting that inhibition of HDAC may be a suitable restorative avenue for neurodegenerative diseases (32). In this study, we examined the effects of VPA on AD neuropathology and behavioral deficits and recognized its underlying mechanism. We found that VPA inhibited GSK-3mediated -secretase cleavage of APP both in vitro and in vivo. Furthermore, such inhibition decreased A production and neuritic plaque formation, as well as alleviated the memory space deficits in AD transgenic model mice. Our data suggest that VPA is effective for antiamyloid therapy in the prevention and treatment of AD. == RESULTS == == VPA inhibits A deposition and neuritic plaque formation in AD transgenic mice == To assess the effect of ML348 VPA treatment on AD neuropathology, APP23 transgenic mice, which are an AD mouse model, were subjected to VPA treatment. APP23 mice carry the human being Swedish mutant APP751 transgene driven by the neuronal-specific Thy1.2 promoter (Fig. S1, available athttp://www.jem.org/cgi/content/full/jem.20081588/DC1). APP23 mice develop amyloid plaques in the neocortex and hippocampus as early as 6 mo (33). APP23 mice were treated with 30 mg/kg VPA at 7 mo of age, whereas age-matched control APP23 mice received vehicle solution. To investigate whether VPA treatment could result in neuropathological changes in vivo, VPA-treated and control mice were killed after treatment and behavioral assessments. 4G8 immunostaining and thioflavin S staining were used to detect A-containing neuritic ML348 plaques in the brain (Fig. 1, A and B). Neuritic plaque formation was significantly decreased in APP23 mice treated with VPA (Fig. 1 A, b), relative to controls (Fig. 1 A, a). Quantification showed that overall VPA treatment reduced plaque number by 4-fold (3.5 0.79 vs. 14.95 2.09 per slice; P < 0.0001;Fig. 1 D). The effects were similar.